Thursday, April 04, 2019 1:24:03 PM
They are like an incubator. ETON is having an offering soon.
From their latest 10K. -
We have ownership positions in Eton, Surface, Melt, and Mayfield and hold royalty interests in certain of their drug candidates. These companies are pursuing market approval for their drug candidates under the FDCA, including under the abbreviated pathway described in Section 505(b)(2) which permits the submission of a new drug application (NDA) where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. In 2018, we formed our Radley and Mayfield subsidiaries We intend to pursue our business strategies though subsidiaries and royalty interests that will focus on the development and FDA approval of certain proprietary drug formulations that we currently own, will in-license/acquire and/or otherwise develop.
From their latest 10K. -
We have ownership positions in Eton, Surface, Melt, and Mayfield and hold royalty interests in certain of their drug candidates. These companies are pursuing market approval for their drug candidates under the FDCA, including under the abbreviated pathway described in Section 505(b)(2) which permits the submission of a new drug application (NDA) where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. In 2018, we formed our Radley and Mayfield subsidiaries We intend to pursue our business strategies though subsidiaries and royalty interests that will focus on the development and FDA approval of certain proprietary drug formulations that we currently own, will in-license/acquire and/or otherwise develop.
saving nickels saving dimes
working till the sun don't shine
looking forward to happier times
1963, Roy Orbison - On Blue Bayou
Recent HROW News
- Harrow to Present at William Blair’s 46th Annual Growth Stock Conference • GlobeNewswire Inc. • 05/27/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 09:00:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/11/2026 08:31:32 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/11/2026 08:20:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 08:10:43 PM
- Harrow Announces First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/11/2026 08:05:00 PM
- Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026 • GlobeNewswire Inc. • 04/27/2026 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 08:07:30 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 08:05:43 PM
- Harrow Announces the Issuance of J-Code for IOPIDINE® 1% • GlobeNewswire Inc. • 04/16/2026 11:00:00 AM
- LogiCare3PL Selected as Distribution Partner by Harrow • PR Newswire (US) • 04/14/2026 02:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 08:05:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 08:58:32 PM
- Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030 • GlobeNewswire Inc. • 03/24/2026 08:57:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 12:16:17 PM
- Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth • GlobeNewswire Inc. • 03/24/2026 12:15:00 PM
- Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting • GlobeNewswire Inc. • 03/18/2026 11:00:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 03/11/2026 06:50:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 12:26:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:05:14 PM
- Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference • GlobeNewswire Inc. • 03/04/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:05:17 PM
- Harrow Wins FDA Clearance to Launch Phase 3 Trial Aimed at Expanding TRIESENCE Label in Cataract Surgery • IH Market News • 03/03/2026 03:39:49 PM
- Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication • GlobeNewswire Inc. • 03/03/2026 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 09:31:33 PM
